CNTNAP3

Across TCGA pan-cancer cohorts, CNTNAP3 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated CNTNAP3 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher CNTNAP3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CNTNAP3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, UCEC, and CHOL are the cancer types where CNTNAP3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.108	0.797	<.001	24	view →
UCEC	DFS	Median	II,III,IV	0.880	0.302	.013	18	view →
CHOL	DFS	Median	All	0.045	0.486	.009	15	view →
PCPG	DFS	Median	All	0.047	0.772	<.001	15	view →
LGG	OS	Median	All	0.474	0.812	.012	5	view →
SARC	DFS	Median	All	0.221	0.610	<.001	4	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
LUAD	DFS	Median	II,III,IV	0.098	0.651	.001	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

CNTNAP3–LUSC (DFS)

Open the LUSC breakdown →